Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes

Purpose: The aim of this study was to evaluate the effect of switching treatment in eyes with neovascular age-related macular degeneration (nAMD) and treatment intervals of ≤6 weeks to brolucizumab. Methods: In this prospective series, eyes with persisting retinal fluid under aflibercept or ranibizu...

Descripción completa

Detalles Bibliográficos
Autores principales: Haensli, Christof, Pfister, Isabel B., Garweg, Justus G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235134/
https://www.ncbi.nlm.nih.gov/pubmed/34204266
http://dx.doi.org/10.3390/jcm10122666

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235134/
https://www.ncbi.nlm.nih.gov/pubmed/34204266
http://dx.doi.org/10.3390/jcm10122666

Ejemplares similares